Prostate Specific Antigen Screening

References 

1. D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440
   • CrossRef
2. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215
   • MEDLINE
3. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol. 2005;23:441
   • MEDLINE
   • CrossRef
4. Gjertson CK, Asher KP, Sclar JD, Katz AE, Goluboff ET, Olsson CA, et al. Local control and long term disease free survival following radical prostatectomy for D1 prostate cancer in the PSA era. J Urol. 2004;171(suppl):385;abstract 1461
5. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447
   • MEDLINE
   • CrossRef
6. House JS, Williams DR. Understanding and reducing socioeconomic and racial/ethnic disparities in health. In:  Smedley BD,  Syme SL editor. Promoting Health: Intervention Strategies from Social and Behavioral Research. New York: National Academies Press; 2000;p. 81–124